GREENWOOD VILLAGE, Col. (TheStreet) -- Ampio Pharmaceuticals (AMPE) announced Monday "positive clinical trial results" from a study of a low-dose generic steroid in diabetic macular edema that looks much more like a failure.
The study in question enrolled 32 patients with diabetic macular edema (DME), or swelling of the central portion of the retina caused by damaged and leaky blood vessels. DME can occur in patients with diabetes, and if untreated, can lead to blindness.
Ampio treated the 32 DME patients with one of three oral doses of Optina, a low-dose reformulation of the generic steroid danazol, or a placebo. Ampio claims low doses of danazol can reverse inflammation thereby making blood vessels less leaky. To test this theory, the Optina study's primary endpoint was the reduction of macular edema after four and 12 weeks of treatment, assessed using a device that measures the thickness of the retina.
The Optina study failed. No statistically significant difference in retinal thickness was measured between patients treated with any three of the Optina doses compared to a placebo. The only glimmer of optimism came from the lowest dose of Optina showing a trend towards reduced retinal thickness over placebo; that result, however, was not statistically significant, Ampio said.The highest dose of Optina tested in the study didn't produce a benefit for DME patients, according to an Ampio statement issued in March. On Monday, Ampio said nothing about the performance of mid- and high-dose Optina dose groups, but Vaughan Clift, Ampio's chief regulatory officer, told me in a phone call Monday that no significant benefit in either the middle or high-dose Optina patients was observed in the study. Yet Clift strongly disagreed with any suggestion that the Optina study was a failure. He insisted that not only was the study an absolute success, but the data show Optina to be "the most exciting development in diabetic eye care in the last 30 years… We can stop blindness." Really? True, if you believe in Ampio's spin, er… I mean… interpretation of data reportedly demonstrating Optina can reduce retinal thickening as long as the dose is aligned correctly with the body mass index (BMI) of the patient.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV